Frontier IP portfolio company Exscientia in Covid collaboration with Gates Foundation


Frontier IP Group PLC (AIM:FIPP) portfolio company Exscientia has signed a US$70mln collaboration with the Bill & Melinda Gates Foundation to develop anti-viral therapeutics against coronavirus and other pandemic viruses.

The four-year agreement will fund work into small molecule therapeutics with less susceptibility to variants and greater patient access than current approaches, Exscientia said in a statement.

Exscientia will use its technology platform and in-house expertise to discover and develop five phase 1-ready assets with the Gates Foundation to provide knowledge in antivirals and global public health

The collaboration will initially focus on developing broad-spectrum Coronavirus agents (e.g., SARS-CoV-2 and its variants, MERS), including accelerating Exscientia’s lead program, which targets the main protease (Mpro) of SARS-CoV-2, the virus responsible for COVID-19.

“The ongoing COVID-19 pandemic underscores the urgency to develop safe and effective broad-spectrum drugs to expand our armoury against viruses and their variants, said Exscientia chief executive Andrew Hopkins.

“We believe that our AI-driven platform can accelerate the creation of better, more effective therapeutics that can address some of the world’s most critical and emerging health risks.”


Please enter your comment!
Please enter your name here